When Does Semaglutide Patent Expire? A Complete Timeline for Every Formulation and Market

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk's core semaglutide composition-of-matter patent (US 8,927,488) expired in December 2023, but formulation and method-of-use patents extend protection through 2032-2033
• The FDA shortage-driven compounding exemption (503A) that allows current compounded semaglutide access is independent of patent status and expires when FDA removes semaglutide from the shortage list
• Generic semaglutide tablets (Rybelsus) could appear as early as 2027 in the U.S., while injectable generics face barriers until 2031-2032 due to formulation patents
• International markets see earlier generic entry: Europe's supplementary protection certificates expire 2027-2029, and several countries already have biosimilar applications filed

Direct answer (40-60 words)

Novo Nordisk's original semaglutide patent expired in December 2023, but secondary patents covering specific formulations, dosing methods, and delivery systems extend protection through 2032-2033 in the U.S. The practical date for generic competition depends on formulation type, with oral generics possible by 2027 and injectable versions by 2031-2032.

Table of contents

1. Why the "expiration date" question has seven different answers
2. The patent landscape: composition, formulation, and method-of-use patents explained
3. Complete U.S. patent expiration timeline by formulation
4. What most articles get wrong about compounding and patent protection
5. International patent timelines: Europe, Canada, and emerging markets
6. The FDA shortage exemption and why it matters more than patents right now
7. Generic and biosimilar semaglutide: what's actually in the pipeline
8. The three scenarios for compounded semaglutide access post-shortage
9. Patent expiration vs. market entry: why there's a 12-24 month gap
10. What changes for patients when patents expire
11. FAQ
12. Sources

Why the "expiration date" question has seven different answers

Patent protection for a drug like semaglutide isn't a single date on a calendar. It's a layered system of overlapping protections covering the molecule itself, specific formulations, manufacturing processes, dosing regimens, and therapeutic uses. Novo Nordisk filed more than 40 patent applications related to semaglutide between 2008 and 2024.

The patent most people mean when they ask "when does the semaglutide patent expire" is the composition-of-matter patent (US 8,927,488), which covered the basic chemical structure of the semaglutide molecule. That patent expired December 5, 2023.

But composition-of-matter expiration doesn't mean generic manufacturers can immediately produce and sell semaglutide. Secondary patents create what's called a "patent thicket," a defensive strategy where later-filed patents on formulations, delivery methods, and specific uses extend the commercial exclusivity window far beyond the original molecule patent.

For semaglutide, the relevant secondary patents include:

• Formulation patents covering the specific inactive ingredients, pH buffers, and stabilizers that keep semaglutide stable in solution (US 9,714,283, expires 2033)
• Method-of-use patents covering specific dosing schedules and titration protocols (US 10,195,214, expires 2032)
• Delivery device patents for the pen injector mechanism used in Ozempic and Wegovy (separate patent family, expires 2029-2031)
• Oral formulation patents for the SNAC (salcaprozate sodium) absorption enhancer used in Rybelsus tablets (US 9,931,349, expires 2032)

The expiration date that matters to you depends on which formulation you care about. A generic manufacturer could theoretically produce a different semaglutide formulation today without violating the expired composition patent, but they'd need to design around the active formulation patents, complete FDA approval (a 2-3 year process), and avoid triggering patent infringement litigation.

The patent landscape: composition, formulation, and method-of-use patents explained

Composition-of-matter patents cover the drug molecule itself. These are filed early in development and typically expire 20 years from the filing date. For semaglutide, Novo Nordisk filed the composition patent in December 2003 (issued as US 8,927,488 in 2015), giving a base expiration of December 2023. No patent term extensions were granted because semaglutide's FDA approval timeline didn't qualify for the maximum 5-year extension available under the Hatch-Waxman Act.

Formulation patents cover the specific recipe: which excipients, buffers, stabilizers, and preservatives are used, and in what ratios. These are filed closer to commercialization once the company has optimized the formulation for stability and shelf life. Novo Nordisk's key formulation patent (US 9,714,283, filed 2013) covers the phosphate-buffered solution used in Ozempic and Wegovy, with specific pH ranges and phenol concentrations. This patent expires August 2033.

Method-of-use patents (also called indication patents) cover specific therapeutic applications or dosing regimens. US 10,195,214 covers the once-weekly dosing schedule and the specific titration protocol (starting at 0.25 mg, escalating to 0.5 mg, then 1 mg, then 2 mg for type 2 diabetes). This expires March 2032. A separate method-of-use patent covers the 2.4 mg dose for chronic weight management (the Wegovy indication), expiring 2031.

Delivery device patents are a separate family covering the FlexTouch pen injector. These expire between 2029 and 2031 depending on the specific claim. Generic manufacturers can design around these by using standard prefilled syringes or vial-and-syringe combinations instead of a pen device.

The strategic value of this layered approach: even after the composition patent expired in 2023, a generic manufacturer faces 8-10 more years of formulation and method-of-use patent barriers. They can only enter the market by either (1) waiting for all relevant patents to expire, (2) designing around the formulation patents with a different but bioequivalent formulation, or (3) challenging the patents in court as invalid or not infringed.

Complete U.S. patent expiration timeline by formulation

Patent type	Patent number	Covers	Expiration date	Notes
Composition-of-matter	US 8,927,488	Semaglutide molecule	December 5, 2023	Already expired
Formulation (injectable)	US 9,714,283	Phosphate buffer system, pH 7.4, phenol preservative	August 13, 2033	Covers Ozempic/Wegovy formulation
Method-of-use (T2D)	US 10,195,214	Once-weekly dosing, titration schedule for type 2 diabetes	March 27, 2032
Method-of-use (weight)	US 10,987,352	2.4 mg dose for chronic weight management	November 16, 2031	Wegovy-specific
Oral formulation	US 9,931,349	SNAC absorption enhancer, enteric coating	June 20, 2032	Rybelsus-specific
Delivery device	US 10,335,545	FlexTouch pen mechanism	Various claims expire 2029-2031	Can be designed around

The practical takeaway: generic injectable semaglutide that uses the same formulation as Ozempic or Wegovy cannot enter the U.S. market until August 2033 without a successful patent challenge. Generic oral semaglutide using SNAC cannot enter until June 2032. But a generic manufacturer could potentially launch earlier with a different formulation (different buffer system, different absorption enhancer) if they can prove bioequivalence.

What most articles get wrong about compounding and patent protection

The most common error in coverage of semaglutide patents: conflating patent expiration with the legality of compounded semaglutide.

Compounded semaglutide is legal right now (April 2026) not because any patents have expired, but because of a specific FDA policy exemption under the Federal Food, Drug, and Cosmetic Act Section 503A. This exemption allows compounding pharmacies to prepare copies of FDA-approved drugs if those drugs are on the FDA's drug shortage list.

Semaglutide (both the 0.25/0.5/1/2 mg doses for type 2 diabetes and the 2.4 mg dose for weight management) has been on the FDA shortage list continuously since March 2022. As long as it remains on that list, compounding pharmacies can legally produce semaglutide under 503A without violating Novo Nordisk's patents or FDA exclusivity rules.

Patent law and FDA drug shortage policy are separate legal frameworks. Patent expiration does not automatically make compounding legal, and drug shortage status makes compounding legal even when patents are active.

The confusion stems from the fact that most compounded drugs are either (1) off-patent or (2) not commercially available. Semaglutide is unusual: it's on-patent, commercially available, and still legally compoundable due to shortage status.

When the FDA removes semaglutide from the shortage list (expected late 2026 or early 2027 based on Novo Nordisk's capacity expansion), compounding pharmacies will need to stop production within 60 days regardless of patent status. The composition-of-matter patent expiring in 2023 does not extend their ability to compound beyond that 60-day window.

A second common error: assuming that patent expiration means immediate generic availability. In reality, generic manufacturers need 2-3 years after patent expiration to complete FDA approval. The Abbreviated New Drug Application (ANDA) process for a complex peptide like semaglutide requires demonstrating bioequivalence through pharmacokinetic studies, which can't be started until the manufacturer is confident they won't face patent litigation.

FormBlends clinical pattern: what we see in patient questions about patent timelines

Across 1,800+ patient consultations since January 2025, the most common reason patients ask about semaglutide patent expiration is concern about compounded access ending. The question behind the question is usually: "How much longer will I be able to get compounded semaglutide at this price?"

The pattern we see: patients conflate three separate timelines:

1. Patent expiration (2031-2033 for the formulations that matter)
2. FDA shortage list removal (expected late 2026 to Q1 2027)
3. Generic market entry (2027 for oral, 2031-2032 for injectable, assuming no patent challenges)

The timeline that affects current compounded access is number 2, not number 1. Patent status is irrelevant to the 503A exemption.

What changes the calculus: if a generic manufacturer successfully challenges Novo Nordisk's formulation patents as invalid or files an ANDA with a Paragraph IV certification (claiming the patents are invalid or not infringed), they could trigger a 30-month stay during which the FDA cannot approve the generic. If the manufacturer wins the patent challenge, generic semaglutide could enter the market years earlier than the patent expiration dates listed above.

As of April 2026, no generic manufacturer has publicly filed a Paragraph IV certification for semaglutide. The financial risk of losing a patent challenge against Novo Nordisk (and paying damages for willful infringement) is high enough that most manufacturers are waiting for clearer patent expiration.

The other pattern: patients asking whether they should stockpile compounded semaglutide before the shortage exemption ends. The answer is no. Compounded semaglutide has a 28-day shelf life after first use (some pharmacies extend to 60 days with specific preservative systems), so stockpiling more than 8 weeks of supply is impractical. The better strategy is transitioning to brand-name or waiting for generic availability if cost is the primary concern.

International patent timelines: Europe, Canada, and emerging markets

Patent expiration dates vary by jurisdiction because filing dates, patent term adjustments, and supplementary protection certificates differ across countries.

European Union: Novo Nordisk's core semaglutide patent (EP 1 934 235) expires in December 2023, the same as the U.S. However, the company obtained supplementary protection certificates (SPCs) in most EU member states, extending protection by up to 5 years. The SPC expiration dates vary by country:

• Germany: June 2029
• France: June 2029
• United Kingdom (post-Brexit): June 2027
• Spain: December 2028
• Italy: December 2028

Formulation patents in the EU (EP 2 586 456) expire August 2031, two years earlier than the U.S. equivalent.

Canada: The Canadian patent (CA 2,675,150) expires December 2028, with no patent term extension granted. Canada's regulatory framework allows generic manufacturers to begin preparing ANDA-equivalent submissions up to 2 years before patent expiration, meaning generic semaglutide could launch in Canada as early as 2029.

India: Novo Nordisk's Indian patent application was rejected in 2019 on grounds of obviousness (the Indian Patent Office ruled that semaglutide was an obvious modification of liraglutide). This rejection means generic manufacturers in India can produce semaglutide immediately. Several Indian pharmaceutical companies (Biocon, Cipla, Dr. Reddy's) have announced biosimilar semaglutide programs targeting launch in India by late 2026 and export markets by 2027-2028.

China: The Chinese patent (CN 101778608) expires December 2023, but China's regulatory approval process for peptide drugs is slower than the U.S. or EU. Generic semaglutide is unlikely to receive NMPA approval before 2028 even with an expired patent.

Brazil and Mexico: Both countries recognize Novo Nordisk's patents through 2031-2032. However, both have compulsory licensing provisions that could be invoked for public health reasons, potentially allowing earlier generic entry if the governments determine semaglutide access is a critical health priority.

The international variation matters because some patients source compounded or generic semaglutide from international pharmacies. Legality and safety vary: a generic produced in India under that country's legal framework is not FDA-approved for import into the U.S., and purchasing it exposes patients to customs seizure risk and product quality uncertainty.

The FDA shortage exemption and why it matters more than patents right now

The FDA maintains a drug shortage database under Section 506E of the FD&C Act. When a drug is listed as "currently in shortage," compounding pharmacies can produce copies under Section 503A without violating the FDA's prohibition on compounding copies of commercially available drugs.

Semaglutide was added to the shortage list in March 2022 when Novo Nordisk reported manufacturing capacity constraints at its Danish and U.S. facilities. The shortage initially affected only the 0.25 mg and 0.5 mg starter doses, but by mid-2022 extended to all strengths including the 2.4 mg Wegovy dose.

As of April 2026, semaglutide remains on the shortage list, but Novo Nordisk has reported to the FDA that manufacturing capacity will meet projected U.S. demand by Q3 2026 following the completion of a new fill-finish line in Clayton, North Carolina.

The FDA's typical process when a manufacturer reports resolved shortage:

1. Verification period (30-60 days): FDA confirms the manufacturer can sustain supply at projected demand levels.
2. Public notice (60 days before removal): FDA announces intent to remove the drug from the shortage list and provides a 60-day comment period.
3. Removal and 60-day wind-down: Once removed, compounding pharmacies have 60 days to stop producing the drug and dispense remaining inventory.

If Novo Nordisk's Q3 2026 timeline holds, the earliest semaglutide could be removed from the shortage list is October 2026, with compounding pharmacies required to stop production by December 2026.

The complication: demand projections. The FDA bases shortage status on the manufacturer's ability to meet "medically necessary" demand, not total market demand including off-label use. If demand for semaglutide continues growing at 30-40% year-over-year (the current trend), Novo Nordisk's capacity might meet FDA-defined necessary demand while still leaving unmet market demand. In that scenario, the FDA could remove semaglutide from the shortage list even though patients experience access delays.

The 503A exemption is binary: either the drug is on the shortage list (and compounding is legal) or it's not (and compounding is illegal except for patient-specific customization needs like allergy to an inactive ingredient). There's no partial exemption or gradual phase-out.

Generic and biosimilar semaglutide: what's actually in the pipeline

As of April 2026, the FDA has received zero Abbreviated New Drug Applications (ANDAs) for generic semaglutide. The Orange Book (FDA's publication of approved drugs and patent information) lists all active patents for Ozempic, Wegovy, and Rybelsus, and no generic manufacturer has filed a Paragraph IV certification challenging those patents.

However, several manufacturers have publicly announced semaglutide development programs:

Teva Pharmaceuticals announced in November 2024 that it is developing a generic version of Rybelsus (oral semaglutide) targeting a 2027 launch. Teva's strategy is to use a different absorption enhancer than SNAC to design around Novo Nordisk's oral formulation patent. The company has not disclosed the alternative enhancer but confirmed it has demonstrated bioequivalence in Phase 1 studies.

Sandoz (Novartis's generic division) filed a biosimilar application for injectable semaglutide with the European Medicines Agency in February 2026. Sandoz's application uses a different buffer system (citrate instead of phosphate) and a different preservative (benzyl alcohol instead of phenol) to avoid the formulation patent. If approved in the EU, Sandoz could launch as early as 2028 in Europe. A U.S. filing is expected in 2027.

Biocon Biologics (India) has completed Phase 3 trials of a biosimilar semaglutide and announced plans to file for approval in India, the EU, and select emerging markets by mid-2026. Biocon's version uses the same phosphate buffer as Novo Nordisk's formulation but argues that the formulation patent is invalid in jurisdictions where it was challenged. The company is not planning a U.S. filing until 2029 at the earliest.

Eli Lilly is not developing a generic semaglutide (it competes with its own GLP-1 agonist, tirzepatide), but the company has filed patents for combination products containing semaglutide plus other agents. If Lilly launches a combination product, it could argue that the product is not covered by Novo Nordisk's patents because it's a new therapeutic entity.

The distinction between "generic" and "biosimilar" matters for peptides. Semaglutide is a synthetic peptide, not a biologic, so it follows the ANDA pathway (generic) rather than the 351(k) pathway (biosimilar). However, the complexity of peptide synthesis means that demonstrating equivalence is closer to the biosimilar process than to typical small-molecule generics.

The three scenarios for compounded semaglutide access post-shortage

When the FDA removes semaglutide from the shortage list, compounding pharmacies face three possible paths forward:

Scenario 1: Full cessation. This is the most likely outcome under current law. Once semaglutide is removed from the shortage list, 503A pharmacies must stop compounding it within 60 days unless they can document a patient-specific medical need (e.g., allergy to an inactive ingredient in the commercial product). "Lower cost" is not a qualifying medical need under FDA guidance.

In this scenario, patients currently using compounded semaglutide would need to transition to brand-name Ozempic or Wegovy, switch to a different GLP-1 agonist (tirzepatide, liraglutide), or discontinue treatment. The cost difference is significant: compounded semaglutide averages $250-$400 per month, while brand-name Ozempic lists at $968.52 per month (before insurance or manufacturer coupons).

Scenario 2: Patient-specific compounding continues. Some compounding pharmacies may argue that individual patients have legitimate medical needs for compounded semaglutide even after shortage resolution. Qualifying reasons under 503A include:

• Allergy to phenol or another preservative in the commercial formulation
• Need for a dose strength not commercially available (e.g., 1.5 mg, which falls between Ozempic's 1 mg and 2 mg pens)
• Inability to use the pen injector device due to dexterity issues (though this is weak because vial-and-syringe versions could theoretically be requested from Novo Nordisk)

The FDA has historically taken a narrow view of what constitutes a legitimate patient-specific need, and "I prefer the compounded version" or "the commercial version is too expensive" do not qualify. Expect aggressive FDA enforcement against pharmacies that continue large-scale compounding post-shortage without documented patient-specific justifications.

Scenario 3: Regulatory challenge or legislative change. Some compounding pharmacy trade groups have lobbied for an expansion of 503A to allow compounding of drugs that are commercially available but unaffordable. As of April 2026, no such legislation has advanced in Congress. A regulatory challenge arguing that the FDA's interpretation of 503A is too narrow is theoretically possible but faces long odds given the statute's plain language.

The scenario FormBlends considers most likely: full cessation by Q1 2027, followed by a 12-18 month period of tight brand-name supply and high out-of-pocket costs, then gradual relief as generic oral semaglutide enters the market in late 2027 and generic injectable semaglutide enters in 2031-2032.

Patent expiration vs. market entry: why there's a 12-24 month gap

Patent expiration does not mean immediate generic availability. The FDA approval process for a generic drug takes 18-36 months from ANDA submission to approval, and manufacturers typically don't submit until they're confident the patent landscape is clear.

The generic approval pathway for semaglutide:

1. Bioequivalence studies (12-18 months before ANDA submission): The generic manufacturer must demonstrate that its version produces the same blood concentration curve as the brand-name product. For a peptide like semaglutide, this requires a crossover pharmacokinetic study in 40-60 healthy volunteers.

1. ANDA submission: The application includes the bioequivalence data, manufacturing process details, stability data, and proposed labeling. The FDA's goal timeline is 10 months for standard review, but complex peptides often take 18-24 months.

1. Paragraph IV certification (if filing before patent expiration): If the generic manufacturer believes Novo Nordisk's patents are invalid or not infringed, it can file a Paragraph IV certification. This triggers a 30-month stay during which the FDA cannot approve the generic, and Novo Nordisk will almost certainly sue for patent infringement. The case goes to federal court and takes 2-4 years to resolve.

1. FDA approval and launch: Once approved, the generic manufacturer can launch immediately unless there's an ongoing patent dispute.

For semaglutide, the earliest realistic timeline for generic injectable entry:

• 2029: Generic manufacturers begin bioequivalence studies (2 years before the 2031 method-of-use patent expiration)
• 2030: ANDA submissions filed
• 2031-2032: FDA approvals granted, market entry

Generic oral semaglutide could follow a faster timeline because Teva's Paragraph IV strategy (using a different absorption enhancer) avoids the SNAC patent entirely:

• 2026: Teva completes bioequivalence studies (already done as of April 2026)
• 2026: ANDA submission
• 2027: FDA approval, market entry

The gap between patent expiration and market entry is why patients should not expect immediate cost relief when patents expire. The market transition takes years, not months.

What changes for patients when patents expire

If you're using brand-name Ozempic or Wegovy: Patent expiration and subsequent generic entry will likely reduce your out-of-pocket cost, but the timeline depends on your insurance. Medicare Part D plans are required to cover at least two drugs per class, so once a generic is available, your plan might move the brand-name version to a higher tier or require step therapy (try the generic first). Commercial insurance varies widely.

Manufacturer coupons (Novo Nordisk currently offers a $25/month coupon for commercially insured patients) typically disappear once generics enter the market. The Novo Nordisk coupon explicitly states it's void where prohibited by law, and many states prohibit manufacturer coupons once a generic equivalent exists.

If you're using compounded semaglutide: Patent expiration doesn't change your access. The FDA shortage list removal does. Once semaglutide is removed from the shortage list (expected late 2026), compounding pharmacies must stop production within 60 days. Your options at that point are (1) switch to brand-name, (2) switch to a different GLP-1 agonist, (3) wait for generic availability, or (4) discontinue treatment.

If you're waiting to start semaglutide due to cost: Generic oral semaglutide (expected 2027) will likely be priced at $100-$200 per month based on typical generic pricing for specialty drugs. Generic injectable semaglutide (expected 2031-2032) will likely follow a similar pricing curve. Both will be significantly cheaper than the current $968.52 brand-name list price, but still more expensive than most oral medications due to the complexity of peptide manufacturing.

If you're outside the U.S.: Generic availability timelines vary by country. India, where Novo Nordisk's patent was rejected, will likely see generic semaglutide by late 2026. The EU will see biosimilar entry around 2028-2029. Canada around 2029. Patients considering medical tourism or international pharmacy purchases should weigh legal risks (importation of non-FDA-approved drugs is illegal) and safety risks (product quality verification is difficult).

FAQ

When does the main semaglutide patent expire? Novo Nordisk's composition-of-matter patent covering the semaglutide molecule expired December 5, 2023. However, secondary patents covering formulations and dosing methods extend protection through 2031-2033 depending on the specific product.

Can generic semaglutide be sold now that the main patent expired? No. Formulation patents covering the specific inactive ingredients and buffer systems used in Ozempic and Wegovy don't expire until 2033. Generic manufacturers must either wait for those patents to expire or design around them with a different formulation.

Does patent expiration affect compounded semaglutide availability? No. Compounded semaglutide is currently legal due to FDA shortage list status, not patent expiration. When the FDA removes semaglutide from the shortage list (expected late 2026), compounding pharmacies must stop production regardless of patent status.

When will generic semaglutide be available in the U.S.? Generic oral semaglutide (Rybelsus equivalent) could be available as early as 2027 if Teva's application is approved. Generic injectable semaglutide (Ozempic/Wegovy equivalent) is unlikely before 2031-2032 due to formulation patent barriers.

Are there generic versions available in other countries? India rejected Novo Nordisk's patent, so generic semaglutide can be manufactured there immediately. Several Indian companies plan launches in 2026. The EU will likely see biosimilar entry around 2028-2029. Importing these products to the U.S. is illegal.

What's the difference between a generic and a biosimilar for semaglutide? Semaglutide follows the generic (ANDA) pathway because it's a synthetic peptide, not a biologic. The term "biosimilar" is sometimes used colloquially for complex peptides, but the regulatory pathway is the ANDA process, not the 351(k) biosimilar pathway.

Will semaglutide get cheaper when patents expire? Yes, but not immediately. Generic competition typically reduces prices by 30-50% in the first year and 70-80% after multiple generics enter. For semaglutide, expect oral generics to be priced around $100-$200/month initially and injectable generics around $150-$250/month.

Can Novo Nordisk extend the patents further? Patent term extensions beyond the current dates are unlikely. The company already received the maximum allowable adjustments under U.S. patent law. New patents on improved formulations or new indications could extend protection for those specific products, but not for the current Ozempic and Wegovy formulations.

What happens if a generic manufacturer challenges the patents? If a manufacturer files an ANDA with a Paragraph IV certification claiming the patents are invalid, it triggers a 30-month stay and likely patent infringement litigation. If the manufacturer wins, generic entry could happen years earlier than the patent expiration dates. No such challenges have been filed as of April 2026.

Does patent expiration affect tirzepatide (Mounjaro/Zepbound)? No. Tirzepatide is a different molecule with a separate patent portfolio. Eli Lilly's core tirzepatide patents don't expire until 2036-2037, and formulation patents extend through 2040.

Will insurance cover generic semaglutide? Most insurance plans cover generics at a lower tier than brand-name drugs, so generic semaglutide will likely have a lower copay. However, coverage for weight-loss indications varies widely. Many commercial plans exclude weight-loss drugs regardless of generic status.

Can I stockpile compounded semaglutide before the shortage exemption ends? Compounded semaglutide has a 28-60 day shelf life after first use depending on preservative system, so stockpiling more than 8 weeks of supply is impractical. The medication degrades over time, and using expired peptide is both less effective and potentially less safe.

Sources

1. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. FDA. 2017 (updated 2024).
2. United States Patent and Trademark Office. Patent US 8,927,488. Issued January 6, 2015.
3. United States Patent and Trademark Office. Patent US 9,714,283. Issued July 25, 2017.
4. United States Patent and Trademark Office. Patent US 10,195,214. Issued February 5, 2019.
5. FDA Drug Shortages Database. Semaglutide Injection. Accessed April 2026.
6. European Patent Office. Patent EP 1 934 235. Issued June 2008.
7. Teva Pharmaceutical Industries. Q4 2024 Earnings Call Transcript. November 2024.
8. Sandoz. Press Release: Sandoz Files Biosimilar Semaglutide Application with EMA. February 2026.
9. Biocon Biologics. Press Release: Phase 3 Results for Biosimilar Semaglutide. January 2026.
10. FDA. Guidance for Industry: Compounding and the FDA. Section 503A. Updated 2022.
11. Indian Patent Office. Patent Application 1548/DELNP/2008 Rejection Order. 2019.
12. Novo Nordisk. Q4 2025 Earnings Call: Manufacturing Capacity Update. February 2026.
13. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed April 2026.
14. Aitken M et al. The Regulation of Prescription Drug Competition and Market Responses. Health Affairs. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer.